

Fall Patient Treated with AgFresh® and BioRelease® Heals Without Infection in Three Months

BACKGROUND

CF is an 83-year-old male. He took a fall on April 15, 2023. As a result of the fall, he was transported to the hospital emergency room for care. The treatment for his injuries, were limited to suturing the wound and dry, sterile dressings were applied and the patient was sent home. By the second week of May the patient's wound had opened and become infected.

The patient has a history of prostate cancer, hypertension hyper lipidemia, gout, Crohn's disease and diabetes mellitus type two.

TREATMENT

CF came to the clinic for evaluation on May 9, 2023. At this time, he had a large wound with necrosis and an apparent infection. To determine the bioburden a MicroGen culture of the wound was taken.

The patient was treated with AgFresh and BioRelease. The dressings were changed every other day. After two weeks, the dressings were changed to BioRelease and Adaptec. Compression with Kerlix and ace wrap was used over the Adaptec on the wound. Shortly after starting the AgFresh and BioRelease the patient's pain significantly decreased. For the first two weeks the patient also had a compound antibiotic mixed with AgFresh and BioRelease. He was seen weekly in the office for debridement and dressing.


OUTCOME

Over the course of three months CF showed steady improvement. The patient was healed by August 9, 2023 and released from our care.

5/30/23



6/06/23




6/20/23




7/07/23



7/19/23



8/09/23




CYTOTOXICITY EVALUATIONS

HFF Cell Culture - Normal human foreskin fibroblasts (ATCC SCRC-1041) were cultured in DMEM supplemented with 10% heat-inactivated fetal bovine serum, 2 mM Lglutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. Cells were seed in flat bottom 96 well microtiter plates at 5×10^3 cells per well and incubated at 37°C/5% CO₂ overnight for adherence. Following overnight incubation, cell culture medium was removed and replaced with 100 µL per well of medium. Compound was added in triplicate wells to the cells at 100 µL per well. Compound plus medium allow was evaluated in a single well per concentration as a colorimetric control.

NHEK Cell Culture - Normal human epidermal keratinocytes (Lonza 00192906) were cultured in KGM Gold Keratinocyte medium with supplied growth supplements. Cells were seed in flat bottom 96 well microtiter plates at 2×10^4 cells per well and incubated at 37°C/5% CO₂ overnight for adherence. Following overnight incubation, cell culture medium was removed and replaced with 100 µL per well of medium. Compound was added in triplicate wells to the cells at 100 µL per well. Compound plus medium allow was evaluated in a single well per concentration as a colorimetric control.

HUMAN FIBROBLAST SURVIVAL RATE IN COMMON ANTIMICROBIAL INGREDIENTS



INVESTIGATORS

Michael Lavor, MD is Medical Director of Saguaro Wound Care Clinic. He served as Dept. Chairman for General and Vascular Surgery at Tucson Medical Center, and Chief of Surgery and Staff at El Dorado Hospital. He is board certified in general surgery and fellow in the American College of Surgeons. He's past president of the Rocky Mountain Vascular Surgical Society, a Fellow in the Southwestern Surgical Congress. He was Commander/OIC of a surgical base in Afghanistan, 2012-2013.



Jessica Barcelo (CCMA) is a clinically certified medical assistant. She served two years as clinical lead for an urgent care center with an additional two-years experience as a wound care specialist.

7140 E. Rosewood Street, Suite 110 - Tucson, AZ 85710
Phone (520) 633-1715 • Saguarowoundcare@gmail.com